# Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

> **NCT05316155** · PHASE1,PHASE2 · RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 235 (estimated)

## Conditions studied

- Non-Muscle Invasive Bladder Neoplasms

## Interventions

- **DRUG:** Erdafitinib Intravesical Delivery System

## Key facts

- **NCT ID:** NCT05316155
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-11
- **Primary completion:** 2028-03-30
- **Final completion:** 2029-07-24
- **Target enrollment:** 235 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05316155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05316155, "Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer". Retrieved via AI Analytics 2026-08-15 from https://api.ai-analytics.org/clinical/NCT05316155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*